Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.

Trial Profile

Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Tipifarnib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2018 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Investigational New Drugs.
    • 27 Jan 2018 Results assessing efficacy of combination of tipifarnib and gemcitabine published in the Investigational New Drugs.
    • 01 Jul 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top